BIOMAT Database Logo BIOMAT Database Logo

Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults. 1989

M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
Department of Medicine, Jichi Medical School, Tochigi-Ken Japan.

38 consecutive, previously untreated adult patients with acute non-lymphocytic leukaemia (ANLL) were treated with BHAC-AMP (N4-behenoyl-1-beta-D-arabinofuranosyl-cytosine, aclacinomycin A, 6-mercaptopurine, and prednisolone) therapy between March 1980 and February 1985. 25 patients (65.8%) achieved complete remission (CR). Median CR duration and median survival of patients who achieved CR were 14, and 24 months, respectively. The Kaplan-Meier analysis revealed a probability for remaining in CR of 18.0% at 5 years. Analysis of failure cases revealed that most of them were due to resistant disease. Major toxicities were infection, diarrhoea, liver dysfunction, nausea and vomiting but these were acceptable. The results indicate that BHAC-AMP therapy is comparable to the regimen with daunorubicin and cytosine arabinoside and a further clinical trial is necessary for previously untreated adult patients with ANNL.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
December 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults.
December 1975, Cancer,
M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
January 1994, Cancer chemotherapy and pharmacology,
M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
[Quadruple combination chemotherapy of acute leukemia using daunomycin, cytosine arabinoside, 6-mercaptopurine riboside and prednisolone].
December 1972, [Rinsho ketsueki] The Japanese journal of clinical hematology,
M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
[Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
October 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
[Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
August 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
[Treatment of acute non-lymphocytic leukemia with concurrent administration of N4-behenoyl-beta-D-arabinofuranosylcytosine, aclacinomycin A, 6-mercaptopurine and prednisolone; a pilot study (author's transl)].
March 1981, [Rinsho ketsueki] The Japanese journal of clinical hematology,
M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
Cytosine arabinoside therapy for acute myeloid leukaemia in adults.
September 1971, The New Zealand medical journal,
M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy.
January 1976, The Tohoku journal of experimental medicine,
M Yoshida, and K Suda, and A Tsuboyama, and R Sasaki, and S Kitagawa, and Y Kano, and Y Muto, and F Takaku, and S Sakamoto, and Y Miura
[Treatment of acute myelogenous leukemia with concurrent administration of N4-behenoyl-ara-C, aclacinomycin A, 6-mercaptopurine and prednisolone].
February 1985, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!